Phase I Randomized, Double-Blind, Placebo-Controlled Study on Safety and Pharmacokinetics of Single-Ascending Doses of TGD001 in Healthy Volunteers

The primary objective of this study is to evaluate the **safety** and **pharmacokinetics** of single-ascending doses of TGD001 in healthy volunteers. This is a Phase I randomized, double-blind, placebo-controlled study. The clinical relevance of this objective lies in determining the initial safety profile and pharmacokinetic parameters of TGD001, which are crucial for assessing its potential for further clinical development. No secondary objectives are provided for this study.

The clinical trial involves a study population of **healthy volunteers** who are exclusively male, with an age range corresponding to adults. The sponsor has not provided information regarding the total number of participants. The trial population was selected to exclude vulnerable populations, ensuring a focus on individuals without significant health issues. Lifestyle considerations such as diet, physical activity, and habits were not specified in the available data. The study is designed to assess the safety and pharmacokinetics of single-ascending doses of TGD001, with no specific inclusion or exclusion criteria detailed in the provided information.

The clinical trial is a **Phase I** randomized, double-blind, placebo-controlled study designed to evaluate the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers. The trial is scheduled to commence recruitment on November 18, 2024, and is expected to conclude by May 28, 2025. Participants will be randomly assigned to receive either the investigational product or a placebo, with neither the participants nor the investigators aware of the group assignments, ensuring the double-blind nature of the study.

The trial will involve a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will proceed to the dosing phase, where they will receive the investigational product or placebo. Subsequent follow-up visits will be conducted to monitor safety, collect pharmacokinetic data, and assess any adverse events. The end-of-study visit will mark the completion of the participant's involvement, during which final assessments will be conducted to ensure participant safety and gather concluding data.

The expected duration of participant involvement will vary depending on the specific dosing schedule and follow-up requirements, but it is anticipated to span several weeks. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, withdrawal of consent by the participant, or any other medical or protocol-related reasons deemed necessary by the investigators. The study is structured to ensure rigorous monitoring and adherence to ethical standards throughout its duration.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is November 18, 2024, with an anticipated end date of May 28, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant clinical parameters. The data collection and analysis will be conducted according to the trial's protocol, ensuring rigorous and systematic evaluation of the investigational product's effects. The trial's findings will contribute to the understanding of the investigational product's potential therapeutic benefits and inform subsequent phases of clinical research.